Avivagen Inc. Announces Proposed Non-brokered Private Placement Of Common Shares For Proceeds Of Up To $1.0 Million
**NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.** Ottawa, ON / Business Wire/ October 14, 2022 – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune […]
Avivagen Inc. Announces Results for the Third Quarter Ending July 31, 2022
Ottawa, ON /Business Wire/ September 16, 2022/ Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the third quarter of […]
Avivagen Announces Publication of Peer-Reviewed Article in Food and Chemical Toxicology Journal
Publication of this Scientific Paper on the Safety of Oxidized Beta Carotene is a milestone on the path to broader regulatory clearance to market and sell OxC-beta™ Products in the U.S. and supports wide-spread adoption of the technology around the world Ottawa, ON /Business Wire/ September 7, 2022 /– Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a […]
Avivagen Announces New Dairy Customer in Mexico
Family-owned dairy business with established reputation for high-quality products turning to OxC-betaTM to support quality of milk Order procured through Meyenberg International, Avivagen’s Mexican distribution partner Ottawa, ON /Business Wire/ August 19, 2022 /– Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human […]
Avivagen Announces Receipt of Repeat Order from Asian Customer
Ottawa, ON /Business Wire/ August 11, 2022 /– Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that one of its most important […]
Avivagen Announces Significant Order of OxC-betaTM in Brazil
Ottawa, ON /Business Wire/ August 3, 2022 /– Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce it has secured a significant order […]
Avivagen Announces Sales of Companion Animal Product and Management Change
6,000 pouches ordered via new and existing customers in Taiwan and Mexico Chris Boland departs role as Chief Financial Officer Ottawa, ON /Business Wire/ July 29, 2022 /- Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake […]
Avivagen Inc. Announces Closing Of Third Tranche Of A Private Placement Of Shares And Warrants
Ottawa, ON / Business Wire/ July 6, 2022 – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that it has closed the third tranche (the […]
Avivagen Inc. Announces Options Grant
Ottawa, ON /Business Wire/ June 20, 2022/ Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, announces that its Board of Directors has approved the issuance of […]
Avivagen Announces Successful Completion of Formal Safety and Toxicology Evaluation of Fully Oxidized Beta-Carotene (OxBC)
Ottawa, ON /Business Wire/ June 9, 2022 /- Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that it has completed a series […]